Artwork

NFX에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 NFX 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.
Player FM -팟 캐스트 앱
Player FM 앱으로 오프라인으로 전환하세요!

NFXBio: Why C2i is the World’s First Platform for Cancer Intelligence

48:54
 
공유
 

Manage episode 295861472 series 2528675
NFX에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 NFX 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.
In this episode, James Currier and Omri Amirav-Drory delve into synthetic biology and tech bio, introducing guest Asaf Zviran, CEO of C2I. They discuss the impact of tech bio on industries, strategies for hiring and fundraising in a virtual world, and the balance between science and business in startups. They also explore the future of cancer treatment and provide valuable advice for startup founders.

The team at C2i Genomics is combining cutting-edge genomics and sophisticated AI to provide the world’s first whole-genome cancer intelligence platform, transforming the way cancer is monitored and treated.

C2i uses a blood test that can detect and quantify tiny amounts of residual cancer to better monitor cancer treatment, progression, and recurrence. NFX was an early stage investor in C2i due to their long-term vision and world-changing technology.

Listen to NFX Partner Omri Amirav-Drory talk with Asaf Zviran, Co-founder & CEO of C2i Genomics, about the future of their company, their latest technological breakthroughs, and where the industry is headed in the near future.

Asaf and Omri's conversation begins at 11:15

Visit C2i to learn more - https://c2i-genomics.com/

(0:00) Introduction and Discussion on Synthetic Biology and Tech Bio (1:24) Introduction to Omri Amirav-Drory and NFX Bio (3:03) Impact of Tech Bio on Various Industries and Future Developments (6:28) Introduction to Pete and Liquid Biopsy for Cancer Monitoring (11:18) NFX Bio Investment Thesis and Conversation with Asaf Zviran, CEO and Founder of C2I (25:23) Asaf Zviran on Managing a Diverse Team and Overcoming Challenges (29:43) Hiring, Recruiting, and Fundraising Strategies in a Virtual World (31:20) Balancing Science and Business in a Startup and Transition from Academia to Industry (38:07) End of Part 1 and Transition to Part 2: Series B Funding and Scaling Up (41:46) Overcoming Challenges in Bio Startups and Future of Cancer Treatment (44:51) Advices for Startup Founders and Quick-fire Round (48:25) Closing Remarks and End of Episode
  continue reading

171 에피소드

Artwork
icon공유
 
Manage episode 295861472 series 2528675
NFX에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 NFX 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.
In this episode, James Currier and Omri Amirav-Drory delve into synthetic biology and tech bio, introducing guest Asaf Zviran, CEO of C2I. They discuss the impact of tech bio on industries, strategies for hiring and fundraising in a virtual world, and the balance between science and business in startups. They also explore the future of cancer treatment and provide valuable advice for startup founders.

The team at C2i Genomics is combining cutting-edge genomics and sophisticated AI to provide the world’s first whole-genome cancer intelligence platform, transforming the way cancer is monitored and treated.

C2i uses a blood test that can detect and quantify tiny amounts of residual cancer to better monitor cancer treatment, progression, and recurrence. NFX was an early stage investor in C2i due to their long-term vision and world-changing technology.

Listen to NFX Partner Omri Amirav-Drory talk with Asaf Zviran, Co-founder & CEO of C2i Genomics, about the future of their company, their latest technological breakthroughs, and where the industry is headed in the near future.

Asaf and Omri's conversation begins at 11:15

Visit C2i to learn more - https://c2i-genomics.com/

(0:00) Introduction and Discussion on Synthetic Biology and Tech Bio (1:24) Introduction to Omri Amirav-Drory and NFX Bio (3:03) Impact of Tech Bio on Various Industries and Future Developments (6:28) Introduction to Pete and Liquid Biopsy for Cancer Monitoring (11:18) NFX Bio Investment Thesis and Conversation with Asaf Zviran, CEO and Founder of C2I (25:23) Asaf Zviran on Managing a Diverse Team and Overcoming Challenges (29:43) Hiring, Recruiting, and Fundraising Strategies in a Virtual World (31:20) Balancing Science and Business in a Startup and Transition from Academia to Industry (38:07) End of Part 1 and Transition to Part 2: Series B Funding and Scaling Up (41:46) Overcoming Challenges in Bio Startups and Future of Cancer Treatment (44:51) Advices for Startup Founders and Quick-fire Round (48:25) Closing Remarks and End of Episode
  continue reading

171 에피소드

모든 에피소드

×
 
Loading …

플레이어 FM에 오신것을 환영합니다!

플레이어 FM은 웹에서 고품질 팟캐스트를 검색하여 지금 바로 즐길 수 있도록 합니다. 최고의 팟캐스트 앱이며 Android, iPhone 및 웹에서도 작동합니다. 장치 간 구독 동기화를 위해 가입하세요.

 

빠른 참조 가이드